October 19, 2016 09:22 AM EDT
R&D

Can­cer pow­er­house Roche el­bows its way in­to a check­point show­down with Bris­tol-My­ers, Mer­ck

Arsalan Arif

Founder

Watch out Bris­tol-My­ers Squibb. Roche is com­ing for some of your em­bat­tled lung can­cer busi­ness.

The FDA wast­ed no time in stamp­ing Roche’s up-and-com­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times